The current state of the share price must be starting to concern management?
I'm certainly not interested in taking it up whilst the sp is below the placement price and i don't think anyone else would either?
Am really becoming unsure whether to hang onto AQR any longer as the Joint Venture speel has worn thin with me and the poster that commented on the depth of the assays may have a valid point?